Abstract:
We analyzed the case of a 49-year-old woman with HIV infection off-therapy with poor viro-immunological compensation, not vaccinated for SARS-COV-2, hospitalized for lobar pneumonia and severe COVID19-related respiratory failure in intensive care unit (ICU). The hospitalization was complicated by bacteraemic ventilator-associated pneumonia (VAP) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) isolated on pleural fluid culture, treated with colistin and cefiderocol for about 3 weeks. The molecular research of MDR-AB on transtracheal aspirate was negative following this therapy. The aim is to show the safety, efficacy and tolerability of colistin-based combination therapy with cefiderocol for Acinetobacter baumannii infection in HIV-infected patient.
摘要:
我们分析了一名49岁的HIV感染女性的病例,该患者接受了较差的病毒免疫补偿,未接种SARS-COV-2疫苗,因重症监护病房(ICU)大叶性肺炎和严重COVID19相关呼吸衰竭住院。住院并发由胸水培养分离的多药耐药鲍曼不动杆菌(MDR-AB)引起的细菌性呼吸机相关性肺炎(VAP)。用粘菌素和头孢地洛治疗约3周。经气管抽吸物MDR-AB的分子研究为阴性。目的是为了显示安全,粘菌素与头孢地洛联合治疗对HIV感染患者鲍曼不动杆菌感染的疗效和耐受性。